• ASH Annual Meeting
  • Chronic Leukemias
  • Meeting Coverage
  • Multimedia

Andreas Hochhaus: Asciminib vs. Bosutinib in Chronic Myeloid Leukemia

Monday, December 7, 2020

Andreas Hochhaus, MD, discusses results from a phase I study suggesting asciminib may have superior efficacy to bosutinib in patients with heavily pretreated chronic myeloid leukemia.
Advertisement

SHARE
Sabrina Ahle